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Summary
BACKGROUND: The imaging method most frequently
employed to identify brain areas involved in neuronal pro-
cessing of nociception and brain pain perception is blood
oxygenation level-dependent (BOLD) magnetic resonance
imaging (MRI). Arterial spin labelling (ASL), in contrast,
offers advantages when slow varying changes in brain
function are investigated. Chronic pelvic pain syndrome
(CPPS) is a disorder of, mostly, young males that leads to
altered pain perceptions in structures related to the pelvis.
We aimed to investigate the potential of ASL to monitor
longitudinal cranial blood flow (CBF) changes in patients
with CPPS.
METHODS: In a randomised, placebo-controlled, double-
blind single centre trial, we investigated treatment effects
in CPPS after 12 weeks in patients that underwent sono-
electro-magnetic therapy vs placebo. We investigated
changes of CBF related to treatment outcome using pseu-
do-continuous arterial spin labelling (pCASL)-MRI.
RESULTS: We observed CBF downregulation in the pre-
frontal cortex and anterior cingulate cortex and upregu-
lation in the dorsolateral prefrontal cortex in responders.
Nonresponders presented with CBF upregulation in the
hippocampus. In patients with a history of CPPS of less
than 12 months, there were significant correlations be-
tween longitudinal CBF changes and the Chronic Prosta-
titis Symptom Index pain subscore within the joint clusters
anterior cingulate cortex and left anterior prefrontal cortex
in responders, and the right hippocampus in nonrespon-
ders.
CONCLUSIONS: We demonstrated therapy-related and
stimulus-free longitudinal CBF changes in core areas of
the pain matrix using ASL. ASL may act as a complemen-
tary noninvasive method to functional MRI and single-pho-
ton emission computed tomography / positron emission
tomography, especially in the longitudinal assessment of
pain response in clinical trials. (Trial registration number
NCT00688506)
Key words: perfusion, ASL, pCASL, chronic pelvic pain
syndrome, sham
Introduction
Functional neuroimaging methods have been consistently
employed for more than two decades to study neuronal
correlates of chronic pain. The imaging method most fre-
quently employed to identify brain areas involved into neu-
ronal processing of nociception and brain pain perception
is blood oxygenation level-dependent (BOLD) magnetic
resonance imaging (MRI) [1].A recent meta-analysis of
138 studies of BOLD functional MRI (fMRI) use consis-
tently identified the insular cortex, the somatosensory cor-
tex and the anterior cingulate cortex as core areas being
activated during pain perception, independently from the
paradigms and populations under observation [2]. Arterial
spin labelling (ASL), in contrast to BOLD fMRI, offers
advantages in applications where slow varying changes in
brain function are investigated [3], has considerable po-
tential for the comparison of within- and between- subject
differences associated with pain-induced state changes and
baseline differences in regional cerebral blood flow (CBF)
[4] and is reproducible [5]. Repeated ASL studies revealed
consistent upregulation of CBF in the primary sensory cor-
tex and posterior insula, the latter showing a CBF mod-
ulation highly correlated with pain aggravation and relief
[6, 7]. Here, the ASL signal is straightforward because it
reflects a single physiological process, CBF, which corre-
lates better with the actual site of neuronal involvement
than the BOLD signal [8]. Restitution of, for example, in-
terhemispheric CBF balance related to reorganisation of
the motor network after ischaemic stroke has been identi-
fied with ASL after 3 months [9], and offers a noninvasive
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approach to monitoring long-term attempts of the brain to
reinstate physiological balance (e.g., between motor nodes
after stroke or core areas of the pain matrix as a conse-
quence of neuromodulating therapies).
We aimed to investigate the potential of ASL to monitor
longitudinal CBF changes in patients with chronic pelvic
pain within a randomised, placebo-controlled, double-
blind single centre trial [10]. We asked if longitudinal CBF
changes in core areas of the pain matrix segregate patients
responding to therapy from nonresponders. We hypothe-
sised that CBF regulation in core structures of the pain ma-
trix (the somatosensory cortex, the insula, the anterior cin-
gulate cortex and prefrontal cortex) are different in therapy
responders and nonresponders.
Patients and methods
Patients
In accordance with the European Association of Urology
(EAU) guidelines [11], all patients with chronic pelvic pain
syndrome (CPPS) enrolled into this study reported pain
perceived in structures related to the pelvis for at least 3
months without proven infection or other related patholo-
gies. All patients underwent detailed urological evaluation,
including medical history, physical examination, urinaly-
sis, determination of prostate-specific antigen (PSA), free
uroflowmetry and post-void residual measurement. Chron-
ic bacterial prostatitis was excluded by means of the Mear-
es-Stamey 3-glass test and negative post-prostatic massage
urine culture. Inclusion criteria were National Institutes
of Health Chronic Prostatitis Symptom Index (NIH-CP-
SI) total score ≥15, NIH-CPSI pain subscore ≥8 and un-
successful stepwise, multimodal therapy with a minimum
of one antibiotic cycle with doxycycline for at least 4
weeks, including antibiotic therapy of the sexual partner,
nonsteroidal anti-inflammatory drug treatment and alpha-
blocker therapy for at least 6 weeks. All patients included
in the study were checked for right-handedness. Patients
with urinary tract infection, post-void residual >100 ml,
prostate cancer, urethral stricture, age <18 years, claus-
trophobia, magnetic implants (cardiac pacemakers, neu-
rostimulators, pain/insulin pumps) were excluded.
This neuroimaging study was part of a randomised con-
trolled trial [10] approved by the local ethics committee
(Kantonale Ethikkommission Bern/3010 Bern/Switzer-
land/Nummer 292-07) and registered with ClinicalTri-
als.gov (trial registration number NCT00688506). All par-
ticipants provided written informed consent before inclu-
sion in the trial. The study conforms to the CONSORT
statement.
Study design and procedures
Study participants were recruited in the urological outpa-
tient clinic and randomly allocated to sono-electro-magnet-
ic or sham therapy based on computer-generated random
numbers with a randomisation ratio of 1:1 and a block size
of 60. The trial included four clinical and two neuroimag-
ing assessment time-points. Baseline assessments included
screening and collection of baseline data followed by high-
resolution structural MRI and ASL perfusion imaging of
the brain. Clinical follow-up assessments were performed
after 6 and after 12 weeks of therapy. MRI was repeated af-
ter 12 weeks. Data collection was closed 16 weeks after a
final clinical assessment. Treatment response was defined
as a decrease in four points on the NIH-CPSI [12].
Imaging data
Structural and CBF data acquisition
All MRI scans were performed on a 3T Siemens Magne-
tom Trio (Erlangen, Germany) equipped with a 12-chan-
nel radio frequency head coil. All MRI examinations took
place at the same time of the day, between 14:00 and
16:00. All high-resolution T1-weighted MR images were
obtained with a 3D modified driven equilibrium Fourier
transform (MDEFT) sequence [13] with the following pa-
rameters: repetition time TR = 7.92 ms, echo time TE =
2.48 ms, flip angle = 16°, inversion with symmetric tim-
ing (inversion time 910 ms), 256 × 224 ×176 matrix points
with a field of view (FOV) of 256 mm × 224 mm yielding a
nominal isotropic resolution of 1 mm3 (i.e. 1×1×1 mm), fat
saturation, 12 min. total acquisition time. The functional
images for the measurement of CBF with a pulsed pseudo-
continuous arterial spin labelling (pCASL) technique was
used with the following parameters [14, 15]: TR/TE =
4000/18 ms, FOV = 230 mm2, matrix size = 128 × 128,
(isocentre of the readout slice was 90 mm above labelling
plane), bandwidth 752 Hz/pixel and flip angle (FA) = 25°,
post-label delay = 1500 ms; and labelling duration = 1720
ms. Sixteen axial slices (EPI readout, 3.4 mm in-plane res-
olution, 6 mm slice thickness and 3.0 mm gap) were posi-
tioned parallel to the bi-commissural axis, and were shifted
in z-direction to cover the primary motor area of each sub-
ject. A total of 80 images, i.e., 40 pairs of label and con-
trol images, were recorded in less than 6 minutes. The se-
quence was recorded with 3D PACE (Siemens Erlangen,
Germany) to enable prospective motion correction. Identi-
cal prescription of MR images was achieved by use of the
Siemens auto-align sequence, which automatically sets up
consistent slice orientation based on a standard MRI atlas.
CBF data analysis and CBF quantification
The PCASL images were processed to examine longitudi-
nal differences in cerebral blood flow at rest between the
two cohorts. Preprocessing and analysis of MR data was
performed using SPM8 (Wellcome Trust Centre for Neu-
roimaging, London, UK: http://www.fil.ion.ucl.ac.uk/spm/
software/spm8/, revision 4667) for MATLAB® (7.8.0,
R2009a) and a customised Matlab code. Raw pCASL im-
ages were first realigned to remove movement artefacts
during MRI acquisition. Quantification of CBF flow time
series was based on the equation:
CBF = ( λ × ΔM2 × α × M0 × T1b ) × ( 1e − ω / T1b − e − (τ + ω) / T1b )
The post-label delay (PLD) (ω) = 1500 ms, labelling du-
ration (τ) = 1720 ms, blood/tissue water partition coeffi-
cient λ = 0.9 g/ml and tagging efficiency assumed to be α
= 0.95 [15]. For 3.0T, the decay time for labelled blood,
T1b = 1650 ms, M0 are the equilibrium brain tissue mag-
netisation images. ΔM was calculated by subtraction of all
realigned label and control images. Quantified CBF flow
time-series and average CBF maps for the entire acquisi-
tion were calculated [16, 17]. Then the CBF images were
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co-registered to the individual anatomy and normalised us-
ing the individual normalisation parameters derived from
segmentation (see above). T1w MDEFT images were spa-
tially normalised with a 12-parameter affine transforma-
tion to the SPM template to correct for differences in brain
size. The images were segmented, spatially normalised and
modulated to the customised template in the standardised
anatomic space. CBF maps were constrained to the grey
matter by masking CBF images with normalised grey mat-
ter partitions that were binarised at a density threshold of
0.2. This empirical value assured that GM density values
of at least 68% were included in the GM images. Final-
ly, the CBF images were smoothed with a 3D Gaussian
kernel of 12-mm full width at half maximum (FWHM) to
reduce interindividual anatomical differences and increase
the SNR [3]. Subsequent independent t-tests without equal
variance assumption were computed for group-wise differ-
ences of the mean CBF values.
Statistical analysis
We analysed longitudinal changes in mean CBF within
subjects with SPM, using a flexible factorial design with
time and subject as factors, and taking scans at time-point
1 and 2 and the two time-points as conditions for each sub-
ject. Age and global mean CBF were used as nuisance co-
variates for perfusion analysis. The mean CBF maps were
statistically analysed at an uncorrected cluster-level thresh-
old of p <0.001 followed by a region of interest analysis of
significant clusters in the pain processing pathways using
small volume (e.g., volume at centre of mass coordinates
was defined by a sphere of radius = 5 mm) correction (fam-
ily-wise error corrected p <0.05).
Results
Clinical data
Sixty patients were randomised to sono-electro-magnetic
(n = 30, mean age ± standard deviation 46±14 years) or
sham therapy (n = 30, mean age 42±16 years). MR datasets
were incomplete in 8 of 60 patients. After 12 weeks of
treatment, 31 patients responded to therapy and 21 did not.
The 31 responders comprised 16 of 24 patients with active
device (positive treatment response rate 67%) versus 15 of
28 patients with sham device (positive treatment response
rate 54%) (p = 0.11). Treatment responders were younger
than nonresponders (mean age 39±13 vs 53±13 years, p =
0.0003). Mean pain duration in the responder group was 38
days (SD 76 days) and in the nonresponder group 57 days
(SD 59 days; p = 0.36). Fifty patients (23 and 27 patients
with active and sham devices, respectively) were includ-
ed into the ASL study; two ASL datasets (one patient with
active device, one patient with sham device and both with
positive treatment response) had to be excluded owing to
movement artefacts and low image quality at least one of
the two time-points.
Longitudinal CBF differences 12 weeks after sono-
electro-magnetic versus sham therapy
Verum vs sham effects
To check if longitudinal CBF changes are detectable with
ASL, we first investigated if longitudinal CBF changes
could be observed within specific brain areas associated
with pain perception in patients who received verum com-
pared to those who received sham therapy. We identified
significant longitudinal CBF upregulation in the postcen-
tral gyrus and the insula in the nondominant right hemi-
sphere and a CBF downregulation in the prefrontal cortex
(PFC) of the left hemisphere in the verum group. The
largest upregulations were observed in the postcentral
gyrus (ΔCBF 5.03 ml/100g brain tissue/min, interpersonal
variance at time-point 1 43.3, at time-point 2 54.3). In pa-
tients who received sham therapy, we observed increased
CBF in the left dorsomedial and right dorsolateral pre-
frontal cortex. The largest upregulations were observed in
the left dorsomedial prefrontal cortex (DMPFC) (ΔCBF
6.34 ml/100g brain tissue/min; interpersonal variance at
time point 1 90.6, at time point 2 85.9).
Responders vs nonresponders
Patients from both the verum and sham group who re-
sponded to therapy showed decreased CBF values in the
anterior cingulate cortex (ACC) and left anterior prefrontal
cortex, after 3 months of therapy (fig. 1).
CBF changes in the prefrontal cortex were ΔCBF
˗1.98±5.14 ml/100 g brain tissue/min for responders (in-
terpersonal variance at time point 1 54.6, at time-point 2
54.2). Nonresponders had a ΔCBF ˗0.03±5.52 ml/100 g
brain tissue/min. Longitudinal CBF changes in the ACC
were ΔCBF ˗1.64±5.18 ml/100 g brain tissue/min (inter-
personal variance at time-point 1 22.3, at time-point 2
27.9) for responders and ΔCBF 0.69±6.37 ml/100 g brain
tissue/min for nonresponders.Significant upregulation of
CBF was found in the right dorsolateral prefrontal cortex
(DLPFC): ΔCBF 5.79±7.70 ml/100 g brain tissue/min for
responders (interpersonal variance at time-point 1 93.6, at
time-point 2 70.8), and Δ CBF 1.35±10.98 ml/100 g brain
tissue/min for nonresponders (fig. 2).
Patients who failed to respond presented with longitudinal
CBF upregulation in the right hippocampus: ΔCBF
5.10±11.94 ml/100 g brain tissue/min (interpersonal vari-
ance at time-point 1 77.7, at time-point 2 172.5) (fig. 3). In
contrast, for the responders CBF changes in the same re-
gion were ΔCBF 0.79±6.89 ml/100 g brain tissue/min.
To relate regional CBF changes to clinical outcome, we
performed a correlation analysis for responders and nonre-
sponders with changes in CPSI total score, CPSI pain sub-
Figure 1: Statistical parametric map of longitudinal changes in
mean cerebral blood flow (CBF) in the responder group. Downreg-
ulation of cortical CBF in the left prefrontal cortex and anterior cin-
gulate cortex.
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score, CPSI quality of life subscore and disease duration.
For the whole cohort, we identified no correlation between
the overall CPSI score and regional CBF changes (CPSI
total score p = 0.952). After cohort segregation according
to the duration of their symptoms (dichotomised into ≥1
year vs <1 year) we identified longitudinal CBF decreas-
es within the joint clusters ACC and left anterior prefrontal
cortex (Spearman´s correlation r = ˗0.900, p = 0.037) with
the CPSI pain subscore in responders with a short history
of CPPS (n = 8/31). CBF increases were observed in the
right hippocampus (Spearman´s correlation r = ˗0.98, p =
0.01) for nonresponders (n = 4/19) with short disease du-
ration. Patients with a disease duration >1 year revealed no
correlation (n = 23, r = ˗0.117, p = 0.607 for responders; n
= 15, r = ˗0.16, p = 0.954 for nonresponders). All clusters
are displayed in table 1.
Discussion
In this study, we evaluated longitudinal CBF changes relat-
ed to long-term sono-electro-magnetic versus sham stim-
ulation in brain areas jointly activated by painful stimuli.
The main findings that stand out from our study are: (1)
using ASL, longitudinal long-term CBF regulations are de-
tectable in brain areas either related to nociceptive process-
Figure 2: Statistical parametric map of longitudinal changes in
mean cerebral blood flow (CBF) in the responder group. Upregula-
tion of cortical CBF in the right dorsolateral prefrontal cortex
(DLPFC).
Figure 3: Statistical parametric map of longitudinal changes in
mean cerebral blood flow (CBF) in the nonresponder group. Up-
regulation of CBF in the right hippocampus.
ing or cognitive control of pain perception, dependent on
verum vs sham stimulation; (2) response to therapy was as-
sociated with CBF downregulation along structures relat-
ed to the processing of pain-related affects and attention,
whereas nonresponse was associated with CBF upregula-
tion of pain memory. Whereas pCASL perfusion imaging
has been previously used as an alternative method to mea-
sure cortical changes associated with pain-related short-
term conditions, only one study has examined therapy-
related long-term CBF regulations with this noninvasive
and stimulus-free technique [18].We sought to find out if
pCASL can be employed as a noninvasive surrogate bio-
marker, within a randomised controlled clinical trial that
investigated therapy-related effects in patients suffering
from CPPS. Sono-electro-magnetic therapy did not result
in a significant improvement of clinical symptoms in the
overall cohort of treatment refractory CPPS patients com-
pared with sham therapy (the clinical results of this tri-
al have been published elsewhere [10]), but we identified
downregulation of regional CBF following 12 weeks of
therapy along core structures of the pain processing matrix.
These effects were observed in patients who subjectively
reported an improvement of the overall CPPS score, re-
gardless of whether they received verum or sham therapy,
in the ACC and left PFC. These findings imply that neu-
ronal correlates of subjective pain evaluation are detectable
by ASL in affective-motivational and cognitive-evaluative
areas of the pain matrix without the need to apply noci-
ceptive stimuli. Although similar effects have been demon-
strated on the insula and the ACC using BOLD fMRI,
these studies used experimental pain stimulation to exert
immediate haemodynamic responses to therapy.We as-
sume that these CBF changes can be considered mean-
ingful in chronic pain relief, since statistically significant
downregulation in the associative pain matrix areas was
only observed in CPPS subjects who had a subjective re-
sponse and, moreover, changes in the nociceptive matrix
were seen solely in patients within the verum cohort. By
contrast, patients who failed to respond to therapy revealed
longitudinal upregulation of CBF in brain areas associated
with acquisition and consolidation of long-term memory
of pain experience (the hippocampus [19]), and those who
received sham therapy in the dorsomedial and lateral pre-
frontal cortex, the latter being involved into the mainte-
nance of context information and generation of sham-re-
lated expectations and appraisals [20].In our study, lon-
gitudinal therapy-associated modulations were observed
in brain areas that are crucial both for responsiveness to
Table 1: Main findings after 12 weeks of treatment in the responder
and nonresponder groups.
Group comparison Arterial spin labelling
MNI coordi-
nates
Anatomic location
x y z
Cluster
size
Voxel
T
(degrees
of free-
dom)
Left Prefrontal cortex ˗4 64 24 203 6.18
(1,29)
Left Anterior cingulate cor-
tex
˗10 18 24 63 4.13
(1,29)
Right Dorsolateral prefrontal
cortex
40 38 28 220 4.08
(1,29)
Right Hippocampus 26 ˗4 ˗24 52 5.24
(1,17)
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painful stimuli and to reduced responses to pain after sham
treatment. Although our clinical trial failed to demonstrate
the superiority of sono-electro-magnetic therapy compared
with sham stimulation ( the between-group difference in
the change of the CPSI score from baseline to 12 weeks),
neuroimaging with ASL indicated that the sham stimu-
lation engaged the endogenous pain modulation circuitry
similarly to the verum application. In patients with a short
duration of disease, we observed a modest correlation be-
tween CBF increases and the CPSI pain score. These cor-
relations do not necessarily reflect causal effects of the
therapy on brain activity, but may provide noninvasive in-
formation on the nature of the individual differences that
predispose a person towards showing a larger or smaller
therapy response. The dissociation between CBF changes
and clinical response in patients with short disease dura-
tion, as compared with unresponsiveness in later stages
of the disease, may further indicate duration-related limit-
ed plasticity along the network nodes engaged in success-
ful pain relief. Structural neuroimaging using studies using
voxel-based morphometry, diffusion tensor imaging and
fMRI measuring functional connectivity have consistent-
ly demonstrated that CPPS may leave specific imprints in
the pain matrix, predominantly in the ACC [21–23]. These
areas may thus subserve as a potential target for antinoci-
ceptive interventions such as transcranial magnetic stimu-
lation or MR-based biofeedback in patients who do not re-
spond to standard drug regimen.Although we evaluated a
well-defined patient population, there are limitations that
should be addressed. From a methodological point of view,
the CBF changes observed in this study must be consid-
ered only moderate (up to 6.34 ml/100 g/min). Core areas
of the pain matrix such as the spinoreticular projections,
hypothalamus and thalamus may have been obscured be-
cause of the low signal-to-noise ratio and spatial resolution
of the pCASL sequence, making it less reliable as a method
to detect CBF changes in the brain stem and deep brain nu-
clei. Recent developments of improved pCASL with back-
ground-suppressed 3D acquisitions (GRASE) may further
improve the sensitivity and signal-to-noise ratio of this
technique [24].Since our study design did not incorporate a
control group without intervention, we cannot exclude the
possibility that functional differences might have been ob-
served regardless of intervention. Previous studies demon-
strated placebo-related alterations of functional connec-
tivity within core areas of the pain matrix, such as the
dorsolateral PFC, ACC and dorsomedial PFC [25, 26].
Further studies using a crossover design are needed to an-
swer this important question.Further, the influence of other
covariates (such as fatigue, mood, concomitant disorders,
socioeconomic status, etc.) had to be ignored owing to the
limited sample size. From the perspective of daily clini-
cal practice we aimed to assess a homogenous cohort of
well-defined CPPS patients, especially regarding the strict
inclusion criteria and the use of a generally accepted, dis-
ease-specific validated questionnaire.
Conclusions
In summary, we demonstrated therapy-related and stimu-
lus-free longitudinal CBF changes in core areas of the pain
matrix using ASL. Since baseline metabolic activity is an
important index of resting brain function, it may act as a
complementary noninvasive method to fMRI and single-
photon emission computed tomography / positron emis-
sion tomography, especially in the longitudinal assessment
of pain response in clinical trials.
Financial disclosure
The trial was supported by the Bern University Hospital. Sonodyn
Corporation AG (Solothurn, Switzerland) kindly provided all stimula-
tion devices.
Conflicts of interest
The sponsor of the study had no role in study design, data collection,
data analysis, data interpretation, or writing of the report. All authors
had full access to all the data in the study and responsibility for the
decision to submit for publication. None of the authors has a potential
conflict of interest relevant to this article.
References
1 Ogawa S, Lee TM, Kay AR, Tank DW. Brain magnetic resonance imag-
ing with contrast dependent on blood oxygenation. Proc Natl Acad Sci
USA. 1990;(24):9868–72. http://dx.doi.org/10.1073/pnas.87.24.9868.
PubMed.
2 Jensen KB, Regenbogen C, Ohse MC, Frasnelli J, Freiherr J, Lundström
JN. Brain activations during pain: a neuroimaging meta-analysis of pa-
tients with pain and healthy controls. Pain. 2016;(6):1279–86.
http://dx.doi.org/10.1097/j.pain.0000000000000517. PubMed.
3 Wang J, Alsop DC, Song HK, Maldjian JA, Tang K, Salvucci AE, et al.
Arterial transit time imaging with flow encoding arterial spin tagging
(FEAST). Magn Reson Med. 2003;(3):599–607. http://dx.doi.org/
10.1002/mrm.10559. PubMed.
4 Hodkinson DJ, Krause K, Khawaja N, Renton TF, Huggins JP, Vennart
W, et al. Quantifying the test-retest reliability of cerebral blood flow
measurements in a clinical model of on-going post-surgical pain: A
study using pseudo-continuous arterial spin labelling. Neuroimage Clin.
2013;:301–10. http://dx.doi.org/10.1016/j.nicl.2013.09.004. PubMed.
5 Howard MA, Krause K, Khawaja N, Massat N, Zelaya F, Schumann G,
et al. Beyond patient reported pain: perfusion magnetic resonance imag-
ing demonstrates reproducible cerebral representation of ongoing post-
surgical pain. PLoS One. 2011;(2):e17096. http://dx.doi.org/10.1371/
journal.pone.0017096. PubMed.
6 Segerdahl AR, Mezue M, Okell TW, Farrar JT, Tracey I. The dorsal
posterior insula subserves a fundamental role in human pain. Nat Neu-
rosci. 2015;(4):499–500. http://dx.doi.org/10.1038/nn.3969. PubMed.
7 Maleki N, Brawn J, Barmettler G, Borsook D, Becerra L. Pain response
measured with arterial spin labeling. NMR Biomed. 2013;(6):664–73.
doi: http://dx.doi.org/10.1002/nbm.2911. PubMed.
8 Detre JA, Wang J. Technical aspects and utility of fMRI using BOLD
and ASL. Clin Neurophysiol. 2002;(5):621–34. http://dx.doi.org/
10.1016/S1388-2457(02)00038-X. PubMed.
9 Wiest R, Abela E, Missimer J, Schroth G, Hess CW, Sturzenegger M, et
al. Interhemispheric cerebral blood flow balance during recovery of mo-
tor hand function after ischemic stroke--a longitudinal MRI study using
arterial spin labeling perfusion. PLoS One. 2014;(9):e106327.
http://dx.doi.org/10.1371/journal.pone.0106327. PubMed.
10 Kessler TM, Mordasini L, Weisstanner C, Jüni P, da Costa BR, Wiest R,
et al. Sono-electro-magnetic therapy for treating chronic pelvic pain syn-
drome in men: a randomized, placebo-controlled, double-blind trial.
PLoS One. 2014;(12):e113368. http://dx.doi.org/10.1371/jour-
nal.pone.0113368. PubMed.
11 Fall M, Baranowski AP, Elneil S, Engeler D, Hughes J, Messelink EJ, et
al., European Association of Urology. EAU guidelines on chronic pelvic
pain. Eur Urol. 2010;(1):35–48. Published online September 08, 2009.
http://dx.doi.org/10.1016/j.eururo.2009.08.020. PubMed.
12 Nickel JC, Krieger JN, McNaughton-Collins M, Anderson RU, Pontari
M, Shoskes DA, et al.; Chronic Prostatitis Collaborative Research Net-
work. Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain
syndrome. N Engl J Med. 2008;(25):2663–73. Published online Decem-
ber 19, 2008. http://dx.doi.org/10.1056/NEJMoa0803240. PubMed.
13 Deichmann R, Schwarzbauer C, Turner R. Optimisation of the 3D
MDEFT sequence for anatomical brain imaging: technical implications
at 1.5 and 3 T. Neuroimage. 2004;(2):757–67. Published online Febru-
ary 26, 2004. http://dx.doi.org/10.1016/j.neuroimage.2003.09.062.
PubMed.
14 Dai W, Garcia D, de Bazelaire C, Alsop DC. Continuous flow-driven in-
version for arterial spin labeling using pulsed radio frequency and gradi-
ent fields. Magn Reson Med. 2008;(6):1488–97. http://dx.doi.org/
10.1002/mrm.21790. PubMed.
Original article Swiss Med Wkly. 2017;147:w14454
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 5 of 6
15 Wu WC, Fernández-Seara M, Detre JA, Wehrli FW, Wang J. A theoreti-
cal and experimental investigation of the tagging efficiency of pseudo-
continuous arterial spin labeling. Magn Reson Med. 2007;(5):1020–7.
http://dx.doi.org/10.1002/mrm.21403. PubMed.
16 Federspiel A, Müller TJ, Horn H, Kiefer C, Strik WK. Comparison of
spatial and temporal pattern for fMRI obtained with BOLD and arterial
spin labeling. J Neural Transm (Vienna). 2006;(10):1403–15. Published
online April 11, 2006. http://dx.doi.org/10.1007/s00702-006-0434-5.
PubMed.
17 Jann K, Koenig T, Dierks T, Boesch C, Federspiel A. Association of in-
dividual resting state EEG alpha frequency and cerebral blood flow.
Neuroimage. 2010;(1):365–72. Published online February 17, 2010.
http://dx.doi.org/10.1016/j.neuroimage.2010.02.024. PubMed.
18 Hodkinson DJ, Khawaja N, OʼDaly O, Thacker MA, Zelaya FO,
Wooldridge CL, et al. Cerebral analgesic response to nonsteroidal anti-
inflammatory drug ibuprofen. Pain. 2015;(7):1301–10. http://dx.doi.org/
10.1097/j.pain.0000000000000176. PubMed.
19 Price TJ, Inyang KE. Commonalities between pain and memory mecha-
nisms and their meaning for understanding chronic pain. Prog Mol Biol
Transl Sci. 2015;:409–34. http://dx.doi.org/10.1016/
bs.pmbts.2014.11.010. PubMed.
20 Wager TD, Atlas LY. The neuroscience of placebo effects: connecting
context, learning and health. Nat Rev Neurosci. 2015;(7):403–18.
http://dx.doi.org/10.1038/nrn3976. PubMed.
21 Farmer MA, Chanda ML, Parks EL, Baliki MN, Apkarian AV, Schaeffer
AJ. Brain functional and anatomical changes in chronic prostatitis/
chronic pelvic pain syndrome. J Urol. 2011;(1):117–24. Published online
May 17, 2011. http://dx.doi.org/10.1016/j.juro.2011.03.027. PubMed.
22 Mordasini L, Weisstanner C, Rummel C, Thalmann GN, Verma RK,
Wiest R, et al. Chronic pelvic pain syndrome in men is associated with
reduction of relative gray matter volume in the anterior cingulate cortex
compared to healthy controls. J Urol. 2012;(6):2233–7. http://dx.doi.org/
10.1016/j.juro.2012.08.043. PubMed.
23 Martucci KT, Shirer WR, Bagarinao E, Johnson KA, Farmer MA, Labus
JS, et al. The posterior medial cortex in urologic chronic pelvic pain
syndrome: detachment from default mode network-a resting-state study
from the MAPP Research Network. Pain. 2015;(9):1755–64.
http://dx.doi.org/10.1097/j.pain.0000000000000238. PubMed.
24 Alsop DC, Detre JA, Golay X, Günther M, Hendrikse J, Hernandez-
Garcia L, et al. Recommended implementation of arterial spin-labeled
perfusion MRI for clinical applications: A consensus of the ISMRM per-
fusion study group and the European consortium for ASL in dementia.
Magn Reson Med. 2015;(1):102–16. http://dx.doi.org/10.1002/
mrm.25197. PubMed.
25 Hashmi JA, Baria AT, Baliki MN, Huang L, Schnitzer TJ, Apkarian AV.
Brain networks predicting placebo analgesia in a clinical trial for chron-
ic back pain. Pain. 2012;(12):2393–402. http://dx.doi.org/10.1016/
j.pain.2012.08.008. PubMed.
26 Tétreault P, Mansour A, Vachon-Presseau E, Schnitzer TJ, Apkarian
AV, Baliki MN. Brain Connectivity Predicts Placebo Response across
Chronic Pain Clinical Trials. PLoS Biol. 2016;(10):e1002570.
http://dx.doi.org/10.1371/journal.pbio.1002570. PubMed.
Original article Swiss Med Wkly. 2017;147:w14454
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 6 of 6
